

August 7, 2026

To, National Stock Exchange of India Limited, “Exchange Plaza”, 5th Floor, Plot No. C/1, G Block, Bandra- Kurla Complex, Bandra (East), Mumbai – 400 051	To, BSE Limited, Corporate Relationship Department, 2nd Floor, New Trading Ring, P.J. Towers, Dalal Street, Mumbai – 400 001
Scrip Name: GLENMARK	Scrip Code: 532296
ISIN: INE935A01035	ISIN: INE935A01035
Our Reference No. 43/26-27	Our Reference No. 43/26-27

Dear Sir,

Sub: Intimation of Schedule of Analyst / Institutional Investor Meetings

Pursuant to the relevant provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform details of the Analyst / Institutional Investor meetings to be conducted as under:

Date	Analyst/Institutional Investors/Event	Venue	Type of Meeting	Group / One-on-one
12-08-2026	Emkay Confluence 2026	Mumbai	Physical	Both
17-08-2026	Motilal Oswal 22 nd Annual Investor Conference 2026	Mumbai	Physical	Both
01-09-2026	Elara India Dialogue 2026	Mumbai	Physical	Both
17-09-2026	Kotak Healthcare Forum	Mumbai	Physical	Both

The company will not be disclosing any Unpublished Price Sensitive Information (UPSI) at these meetings. The schedule of the above-mentioned meetings is subject to change due to exigencies on the part of Investor / Company. We request you to take this intimation on record.

Thanking you.

Yours faithfully,

For Glenmark Pharmaceuticals Limited

Rashmi Khandelwal
Company Secretary & Compliance Officer
ACS – 28839

Glenmark Pharmaceuticals Limited

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099

T: 91 22 4018 9999 F: 91 22 4018 9988 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com